Correlation Engine 2.0
Clear Search sequence regions


Sizes of these terms reflect their relevance to your search.

Current antisense oligonucleotide (ASO) therapies for the treatment of central nervous system (CNS) disorders are performed through invasive administration, thereby placing a major burden on patients. To alleviate this burden, we herein report systemic ASO delivery to the brain by crossing the blood-brain barrier using glycemic control as an external trigger. Glucose-coated polymeric nanocarriers, which can be bound by glucose transporter-1 expressed on the brain capillary endothelial cells, are designed for stable encapsulation of ASOs, with a particle size of about 45 nm and an adequate glucose-ligand density. The optimized nanocarrier efficiently accumulates in the brain tissue 1 h after intravenous administration and exhibits significant knockdown of a target long non-coding RNA in various brain regions, including the cerebral cortex and hippocampus. These results demonstrate that the glucose-modified polymeric nanocarriers enable noninvasive ASO administration to the brain for the treatment of CNS disorders. © 2020 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA.

Citation

Hyun Su Min, Hyun Jin Kim, Mitsuru Naito, Satomi Ogura, Kazuko Toh, Kotaro Hayashi, Beob Soo Kim, Shigeto Fukushima, Yasutaka Anraku, Kanjiro Miyata, Kazunori Kataoka. Systemic Brain Delivery of Antisense Oligonucleotides across the Blood-Brain Barrier with a Glucose-Coated Polymeric Nanocarrier. Angewandte Chemie (International ed. in English). 2020 May 18;59(21):8173-8180

Expand section icon Mesh Tags

Expand section icon Substances


PMID: 31995252

View Full Text